Biomarker Services

deep expertise • flexible solutions • close collaboration • rapid delivery

End‑to‑End Biomarker Strategy for Drug Discovery

At Domainex, we offer an integrated, end‑to‑end biomarker discovery and translational assessment capability that supports drug discovery from early identification through to preclinical decision‑making. Our comprehensive suite of technologies, combined with Human Tissue Act accreditation enabling access to primary human cells from healthy and disease state donors, ensures biologically meaningful and clinically relevant insights from the start.

 

Whether you require a hypothesis‑driven strategy or an unbiased multi‑omics approach, our experts deliver high‑quality biomarker data to guide target validation, lead optimisation and translational confidence.

 

 

Why Domainex for Biomarker Services?

 

Expert, multidisciplinary team

At Domainex, immunologists, cell biologists and analytical scientists work together under one roof, bringing deep expertise across proteomics, metabolomics, spectral and traditional flow cytometry, cellular assays and translational pharmacology. This integrated environment ensures efficiency and speed while maintaining scientific rigour at every stage.

 

Flexible, collaborative approach

Every programme is unique. Domainex scientists design bespoke workflows tailored to your scientific objectives and adapt rapidly as new insights emerge, keeping your project moving efficiently and effectively.

 

Translational focus

The team at Domainex are able to evaluate biomarkers in whole blood, PBMCs, isolated immune cell subsets, physiologically relevant cellular systems and in vivo models to ensure the biomarkers we identify are robust, clinically meaningful and decision‑enabling.

Integrated Biomarker Workflow at Domainex

1. Biomarker Identification

Domainex apply state‑of‑the‑art discovery platforms to identify robust, mechanism‑linked biomarkers that inform target engagement and pathway modulation.

Target Expression and Validation

  • RNA‑seq for unbiased target discovery
  • Agnostic readout identification
  • qPCR for targeted confirmation

 

Pathway Modulation and Signalling Biology

  • Whole‑proteome and focused‑panel proteomics (LC‑MS)
  • ELISA, AlphaLISA and automated Western blotting
  • Quantification of pathway engagement and downstream effects

Metabolic and Functional Readouts

  • LC‑MS‑based metabolomics to detect pathway‑level metabolic changes
  • Functional metabolic profiling to link compound activity to mechanism

 

Deep Immune Phenotyping

  • High‑parameter spectral flow cytometry
  • Detection of pharmacodynamic responses in rare or low‑frequency immune subsets

2. Biomarker Evaluation​

Domainex scientists rigorously evaluate biomarkers to confirm pharmacology, define dose–response relationships and understand duration of action.

Mechanism‑Driven Pharmacology

  • Disease‑relevant models using primary human cells, sorted immune cell populations and whole blood
  • Expert immunologists and cell biologists ensuring physiologically relevant outcomes

 

Advanced Cell Isolation Capabilities

  • Magnetic bead‑based enrichment
  • High‑purity fluorescence‑activated cell sorting (FACS)
  • Enabling cell‑specific biomarker assessment and downstream analysis

3. Translational Assessment

Domainex scientists design biomarker programmes with translation in mind, ensuring continuity from in vitro discovery to in vivo model systems.

Quantitative Measurement Across Matrices

  • Biomarker analysis in whole blood, plasma, tissues and isolated cell subsets
  • LC‑MS–based quantitative bioanalysis for sensitivity and reproducibility
  • Hybrid immunopurification–MS workflows enabling detection of low‑abundance biomarkers

Preclinical Translation

  • Alignment of in vitro and in vivo biomarker strategies
  • Support for PK/PD modelling and candidate selection
  • De‑risking progression into preclinical and early‑clinical development